You are here: Companies > Opthea Limited (OPT)

Opthea Limited (OPT)

Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) is an Australian biotechnology company developing diagnostics and biologic therapies for the treatment of cancer and other serious human illnesses. Circadian owns a portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating blood supply.   

 

Product Pipeline

 

Email this page

Print Profile

Subscribe to company

Location:

Melbourne, Australia

Market Cap:

$414 million

No. Shares:

662,808,634

Sector:

Health Care

Website:

http://www.opthea.com

Share Price & Volume

Additional Research

Edison Investment Research September 2013

Alpha Securities Research  6 July 2012

Edison Investment Research 14 Mar 2012

 

 

 

 

 

 

 

 

 

AusBiotech Member

DISCLAIMER: Orient Capital Pty Ltd has taken all reasonable care in publishing the information contained in this Open Briefing®; furthermore, the entirety of this Open Briefing® has been approved for release to the market by the participating company. It is information given in a summary form and does not purport to be complete. The information contained is not intended to be used as the basis for making any investment decision and you are solely responsible for any use you choose to make of the information. We strongly advise that you seek independent professional advice before making any investment decisions. Orient Capital Pty Ltd is not responsible for any consequences of the use you make of the information, including any loss or damage you or a third party might suffer as a result of that use.